ReviewFrontiers in neuroscience2016
Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.
Review in Frontiers in neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 50 citations in OpenAlex.
- Multitargeted Aza-Arylcarboxamides for Neurodegenerative Diseases: Potent Histamine HACS chemical neuroscience · 2026Article
- The dual G9a inhibitor and histamine H3 receptor antagonist A-366 improves repetitive and social behaviors and attenuates neuroinflammation in BTBR T + tf/J mice.Scientific reports · 2026Article
- Rational Design, Synthesis and Pharmacological Evaluation of Chalcones as Dual-Acting Compounds-Histamine HInternational journal of molecular sciences · 2026Article
- Histamine Modulation of the Basal Ganglia Circuitry in the Motor Symptoms of Parkinson's Disease.CNS neuroscience & therapeutics · 2025Review
- 4-Oxypiperidine Ethers as Multiple Targeting Ligands at Histamine HACS chemical neuroscience · 2024Article
- Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer's disease.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Guanidines: Synthesis of Novel Histamine HPharmaceuticals (Basel, Switzerland) · 2023Article
- Benzophenone Derivatives with Histamine HMolecules (Basel, Switzerland) · 2022Article
- Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Biphenylalkoxyamine Derivatives-Histamine HMolecules (Basel, Switzerland) · 2021Article
- G protein-coupled receptors in acquired epilepsy: Druggability and translatability.Progress in neurobiology · 2019Review
- A Photoswitchable Agonist for the Histamine HAngewandte Chemie (International ed. in English) · 2019Article
- Design, synthesis, andMedChemComm · 2019Article
- Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands.PloS one · 2019Article
- Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats.Neuropsychiatric disease and treatment · 2019Article
- Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands.ACS medicinal chemistry letters · 2017Article
- Tracing the Origins of IgE, Mast Cells, and Allergies by Studies of Wild Animals.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the very recent market approval of pitolisant (Wakix®), the interest in clinical applications of novel multifunctional histamine H3 receptor antagonists has clearly increased. Since histamine H3 receptor antagonists in clinical development have been tested for a variety of different indications, the combination of pharmacological properties in one molecule for improved pharmacological effects and reduced unwanted side-effects is rationally based on the increasing knowledge on the complex neurotransmitter regulations. The polypharmacological approaches on histamine H3 receptor antagonists on different G-protein coupled receptors, transporters, enzymes as well as on NO-signaling mechanism are described, supported with some lead structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.